-
Cantor Fitzgerald Reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)
-
Leerink Partners Reiterates Outperform Rating on Eledon Pharamceuticals (ELDN)
-
Eledon reports 100% insulin independence in diabetes trial
-
Eledon receives FDA orphan drug designation for liver transplant drug
-
Eledon completes $57.5 million financing to advance drug trials
-
Eledon reports early diabetes trial results for tegoprubart drug
-
Eledon Pharamceuticals (ELDN) PT Lowered to $8 at Guggenheim
-
Eledon Pharamceuticals (ELDN) PT Lowered to $5 at Leerink Partners
-
Increasing unusual option volume: ELDN TAC MYLS WRBY PUBM MLYS PLNT MTSR DAY
-
Eledon Pharmaceuticals, Inc. (ELDN) Tops Q2 EPS by 9c
-
Craig-Hallum Starts Eledon Pharamceuticals (ELDN) at Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)
-
Cantor Fitzgerald Reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)
-
H.C. Wainwright Assumes Eledon Pharamceuticals (ELDN) at Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on Eledon Pharamceuticals (ELDN)
-
Eledon Pharmaceuticals, Inc. (ELDN) Tops Q1 EPS by 17c
-
Eledon Pharmaceuticals (ELDN) Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
-
H.C. Wainwright Reiterates Buy Rating on Eledon Pharamceuticals (ELDN)
-
Eledon Pharmaceuticals, Inc. (ELDN) Reports In-Line Q3 EPS
-
Eledon Pharmaceuticals (ELDN) Prices $85M Offering at $3.65/sh
-
Eledon Pharma (ELDN) Announces Positive Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation
-
Eledon Pharmaceuticals (ELDN) Files $250M Mixed Shelf

